Understanding Conflicts of Interest

Financial relationships between researchers and pharmaceutical companies are common in medical research, including bladder cancer.These relationships can take various forms,such as research grants,consulting fees,honoraria,and stock ownership. While these collaborations can accelerate the development of new treatments, they also raise concerns about potential conflicts of interest.

A conflict of interest arises when a researcher’s personal financial interests could possibly influence the design, conduct, or reporting of thier research. it’s crucial to understand these relationships to ensure the integrity and objectivity of scientific findings.

“A conflict of interest arises when a researcher’s personal financial interests could potentially influence the design, conduct, or reporting of their research.”

Specific Financial Disclosures

Several researchers in the field of bladder cancer have disclosed financial relationships with pharmaceutical companies. For example:

• nds reports research/consulting relationships with companies including allless, arteer, amera, asetllas, AstraZeneca, aura biosciences, baosciences, squirs, CG Oncology, sankyo, dendreon, glythherx, Inviae, Invitae, Mdxhealth, Merck, Minomic, Novartis, Nusano, Photocure, PFizer, SUMITOMO, TELIX, Tolmar, Tutelix and Urogen.
• TBP reports honoraria from Asterelas, AstraZeneca, Bristol Myrs Squire, ESAI, GILEAD, IPSEN, johnson & Johnson, Mashup, Merck sharp & dohme, Merck Serono, Novartis, PFiizer, Roche and Seagen; consulting or advisory roles with astellas, AstraZeneca, Bristol Myrs Squeb, esai, elxis, Gilead, Incyte, Ipsen, Johnson & johnson, Mashup, Merck sharp & dohme, Merck Serono, marrono, rocheer and seagen; research funding from aseellas, AstraZeneca, Bristol mys Squeb, ESAI, ELDIS, IPSEN, Johnson & Johnson, Merck Sharp & dohme, Merck Serono, Novartis, PFIZER, Roche and Seagen; and travel, accommodations or expenses from Astellas, AstraZeneca, Gilead, ipsen, Merck sharp & dohme, PFizer and Roche.
• J. bedke reports financial interests from Astellas, AstraZeneca, Bristol Myrs Squire, Daichi Sankyo, Eisai, Ipsen, Jansen, Merck Sorono, Merck Sharp & dohme, Pfizer, Roche, Netctor, Nekker, Nekker and membership in the European association of Urology and the Rinal Cell Carcinoma Guidelines Panel (vice-chairman).
• MDG reports stock and other ownership interests in PFizer, Merck and Gilead Sciences; research funding from Merck, Bristol Mys Squebb, Mirati Therapeutics, Seagen, Alliance Foundation Trials, Alliance for clinical Trials in Oncology, Clovis Oncology, Arvinas, Alx Oncology, Hoosier Cancer Research Network, Novartis, Acrivon Therapeutics, astellas, genentech, accuray, pcctc, g1 Therapeutics, October, Flare Therapeutics, Loxo/lilly, Roche and PFizer; other relationships with Elsevier, Medscape and research to practice; UNCOPENEST REICETSIPS: G1 therapeutics and Loxo/Lilly.
• JPR reports advisory/consultancy roles for arquer diagnostics, biotech, bta pharmaceuticals, combat, genoic expression and olympus; Steering Committee Membership for AstraZeneca, Bristol Mys Squebb, Jansen and PFizer; grant or research support from arquer diagnostics, biotech, bta pharmaceuticals, cepheid, taris biomedical and nucleix; and research funding from PFIZER.
• JHK reports research funding from pfizer.
• MK reports research funding from PFizer.
• EX reports consulting or advisory role with pFizer, ferring and boston scientific and research funding from ferring and pFizer.
• BA reports honoraria from AstraZeneca, Astellas, ESAI, Jansen, Bayer, Merck Sharp & Dohme, Merck, PFizer, Roche and Bristol Mys Squebb; consulting or advisory role with AstraZeneca, Astellas, Bayer, Bristol Mys Squebb, Jansen, Merck, PFizer, Merck sharp & dohme, Roche and Eisai; speakers’ bureau for Jansen, Astellas, PFizer, AstraZeneca, Merck, Bristol Mys Squebb, Merck Sharp & Dohme, Eisa and Roche; research funding from AstraZeneca, Merck, Bayern, Asterlas, Jansen, Bristol Mys Squebb, Pfizer, icon Clinical Research, EIII, Merck Sharp & Dohme and Roche; and travel, accommodations and expenses from AstraZeneca, Astellas, Bayer, Bristol mys Squeb, Jansen, Merck sharp & dohme, PFizer and Sanofi.
• DY reports research funding from PFizer.
• FG-R. reports research support/principal investigator roles with Johnson & Johnson, PFIZER, Taris, Bristol Mys Squb, Roche, Seagen, AstraZeneca, Cobat Medical, Cepheid, FIDIA, UROGEN AND Merck sharp & dohme; employment with Sermas (Servicio Madrileño De Saud); consultancy roles with Johnson & Johnson, PFizer, Merck, Roche, Taris, combat Medical, astrazeneca, Merck sharp & dohme and Bristol Mys Squebb; Stockholder: CG Oncology; speakers’ bureau for Jansen, Nucleix, Merck Sharp & Dohme, Merck, Bristol Mys Squbibb, AstraZeneca, Palex, combat Medical, John & Johnson and Recordti; travel expenses paid by PFizer, Record, IPSEN, Combat Medical, Alter, Salvat, Nucleix, AstraZeneca, Fidia and Johnson & Johnson; advisory board member for astrazeneca, Bristol Myrs Squire, Cobat Medical, Johnson & Johnson, Nucleix, PFizer, Taris, Roche and Merck Sharp & Dohme; and manushcript support from PFIZER, Jansen, combat Medical, AstraZeneca, Johnson & Johnson and Bristol mys squip.
• AB reports consulting or advisory roles with Asterlas, jansen-Cilag, Opko Health, MdxHealth, Ferring, Bayer, AstraZeneca, Hauora and pfizer; speakers’ bureau for Asterlas; and research funding from Sandoz-novers, Merck sharp & dohme and Pfize.
• GSK reports honoraria from Abbvie, Terseera, Bayer, Knight Pharmaceuticals, AstraZeneca Canada and Photocure; consulting or advisory role with Merck, theralase, jansen Oncology, Ferring, Verity Pharmaceuticals, Bristol Mys Squibb, Emd Serono, PFIZER, Novartis and Engene; research funding from Johnson & Johnson/Janssen and PFIZER.
• J. Binkmann reports employment with Pfizer Pharma Gmbh.
• A.-MC reports employment with Pfizer Srl.
• RC REPORTS employment with PFIZER SRL.
• AE reports employment with PFIZER Ltd.
• EM reports employment with PFIZER INC.
• JV reports employment with PFIZER INC.
• CW reports employment with PFIZER INC.
• GDS reports advisors/consultancy roles with Heat Biology, CG Oncology, Photocure, Merck, Roche/Genentech, Ciclomed, Taris Biomedical (Now Janssen), Mdxhealth, fidia Farmaceutic, Urogen, Ferring, Boston Scientific,, Bristol Mys Squire, astrazeneca, PFizer, Jansen, Epivax therapeutics, Natera, FKD, Engene Bio, Sesen Bio, Biocancell (Now Archiano), Nucleix, ipsen, Cobat Medical, Astellas, Astellas, Fergen, Dendreon, ABVEIX. verity pharmaceuticals, regenneron, stimit, vyriad, protara, xcures, nonagen, nanology and imvax; Clinical Trial protocol Commission Membership for Bristol Myrs Squabb, CG Oncology, Fidia, Merck, PFizer, Photocure, Protecting and Seagen; Stock/shares in CG Oncology, Engene Bio, epivax therapeutics and urogen; and research funding from P
  

  Share this:

  • Facebook
  • X

  Related

  BiomedicineBladder cancerCancer ResearchgeneralInfectious DiseasesMetabolic DiseasesMolecular MedicineNeurosciences